Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
2023年10月13日 - 5:05AM
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil
Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical
Officer and Interim Head of Research, is participating in a virtual
fireside Q&A at the H.C. Wainwright 4th Annual Hepatitis B
Virus (HBV) Conference on Wednesday, October 25, at 7:00 a.m. PT /
10:00 a.m. ET.
A live webcast of the fireside chat can be
accessed under Events & Presentations in the Investors section
of the Vir website at www.vir.bio and will be archived
there for 30 days.
About Vir BiotechnologyVir
Biotechnology, Inc. is an immunology company focused on combining
cutting-edge technologies to treat and prevent infectious diseases
and other serious conditions. Vir has assembled two technology
platforms that are designed to stimulate and enhance the immune
system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis B and hepatitis delta
viruses, influenza A and B, human immunodeficiency virus and
COVID-19. Vir has several preclinical candidates in its pipeline,
including those targeting RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
Contacts:
Media
Carly Scaduto
Senior Director, Media Relations
cscaduto@vir.bio
+1 314-368-5189
Investors
Sasha Damouni Ellis
Executive Vice President, Chief Corporate Affairs Officer
sdamouni@vir.bio
Vir Biotechnology (NASDAQ:VIR)
過去 株価チャート
から 4 2024 まで 5 2024
Vir Biotechnology (NASDAQ:VIR)
過去 株価チャート
から 5 2023 まで 5 2024